Pharmaron Beijing Co., Ltd.
300759
Rang in Aktien
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Aktienkurs
$5.58
Marktkapitalisierung
$8.24B
Veränderung (1 Tag)
-3.77%
Veränderung (1 Jahr)
28.36%
Land
CN
Handel Pharmaron Beijing Co., Ltd. (300759)
Kategorie
Healthcare
EPS für Pharmaron Beijing Co., Ltd. (300759)
EPS zum June 2026 TTM: $0.15
Laut den aktuellen Finanzberichten und dem Aktienkurs von Pharmaron Beijing Co., Ltd. beträgt das aktuelle EPS des Unternehmens (TTM) $0.15. Am Ende des Jahres 2024 betrug das EPS $0.14 eine Steigerung gegenüber dem EPS von 2023, das $0.13 betrug.
EPS-Verlauf von Pharmaron Beijing Co., Ltd. von 2014 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $0.15 | 11.77% |
| 2025 | $0.13 | -2.89% |
| 2024 | $0.14 | 8.89% |
| 2023 | $0.13 | 12.38% |
| 2022 | $0.11 | -65.77% |
| 2021 | $0.33 | 45.81% |
| 2020 | $0.23 | 90.10% |
| 2019 | $0.12 | 115.94% |
| 2018 | $0.06 | 38.00% |
| 2017 | $0.04 | 20.85% |
| 2016 | $0.03 | -14.03% |
| 2015 | $0.04 | 474.63% |
| 2014 | $0.01 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | 11,820.17% |
US
|
|
| $-7.98 | -5,592.09% |
US
|
|
| $-5.29 | -3,740.74% |
AU
|
|
| $13.70 | 9,328.84% |
BE
|
|
| $27.74 | 18,991.53% |
NL
|
